Is GSK prepping a $1bn takeover bid for IDRx? | pharmaphorum
2 days ago · GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST). The rumoured ...
GSK in Talks to Buy U.S. Rare Tumor Specialist IDRx for up to $1 ...
2 days ago · --Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 billion, the Financial ...
GSK Nears $1 Billion Deal for Biotech Company IDRx
2 days ago · GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology portfolio.
GSK nears $1bn deal for biotech developing drug for rare tumour
2 days ago · GSK nears $1bn deal for biotech developing drug for rare tumour. ... Portfolio FT App FT Digital Edition FT Edit Alerts Hub Business School Rankings Subscription Manager News feed Newsletters ...
GSK is said to be nearing $1B deal to acquire U.S. biotech IDRx
British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout deal to acquire IDRx, a U.S. biotech focused on developing drugs for rare gastrointestinal tumors, The Financial Times reported ...
GSK in advanced talks to purchase U.S. biotech IDRx, FT reports
3 days ago · GSK is in advanced discussions to purchase privately-owned U.S. biotech IDRx, which is working on a treatment for rare gastrointestinal tumors, the Financial Times’ Oliver Barnes and Hannah ...
GSK Nearing Deal to Acquire US Biotech IDRx for Up to $1 Billion
2 days ago · -- GSK is in advanced discussions to acquire privately-owned US biotech company IDRx for up to $1 billion, the Financial Times reported Wednesday, citing people close to the talks. IDRx is developing...
GSK swooping to buy US biotech IDRx for $1bn - report
2 days ago · UK pharma giant GSK PLC is close to buying US biotech startup IDRx for $1 billion to boost its cancer drug business, the Financial Times has reported. ...
GSK nears $1B deal to buy U.S. biotech IDRx (GSK:NYSE)
2 days ago · GSK is said to be nearing $1B deal to acquire U.S. biotech IDRx Jan. 08, 2025 10:19 AM ET GSK plc (GSK) Stock BX By: Dulan Lokuwithana , SA News Editor 2 Comments Play ( 2min )
GSK May Acquire Cancer Specialist IDRx for $1 Billion
09.01.2025 - In a move to expand its oncology business, GSK is nearing a $1 billion deal to buy a US biotech developing a treatment for rare gastrointestinal tumors. According to the newspaper Financial Times, the British pharma group is in advanced talks to buy privately owned biotech company IDRx , citing people close to the discussions.
- Some results have been removed